Setting up a showdown with Boehringer, Pfizer scores interchangeability tag for its Humira biosimilar
Beginning later this month, Pfizer is launching an interchangeable biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug Humira (adalimumab) at a 5% discount on the wholesale acquisition price.
Later in 2023, Pfizer said late last week, its interchangeable biosimilar known as Abrilada (adalimumab-afzb) will be available at a second list price of 60% below the Humira list price.
By contrast, Boehringer Ingelheim, which is the only other company with an interchangeable Humira biosimilar on the market so far, confirmed that its lowest-cost version of its interchangeable known as Cyltezo launched on Oct. 2 with an 81% discount.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
